Literature DB >> 19168793

Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa.

Matin M Imanguli1, William D Swaim, Stacy C League, Ronald E Gress, Steven Z Pavletic, Frances T Hakim.   

Abstract

Although chronic graft-versus-host disease (cGVHD) is a major long-term complication of allogeneic hematopoietic stem cell transplantation, little is known of its pathogenesis. We have systematically examined oral mucosa among cGVHD patients and determined that the clinical severity of oral cGVHD was correlated with apoptotic epithelial cells, often found adjacent to infiltrating effector-memory T cells expressing markers of cytotoxicity and type I cytokine polarization. Accumulation of T-bet(+) T-cell effectors was associated with both increased proliferation and the expression of the type I chemokine receptor CXCR3. Concurrently, in both infiltrating cells and keratinocytes, we observed increased expression of the CXCR3 ligand MIG (CXCL9) and interleukin-15 (IL-15), type I interferon (IFN)-inducible factors that support the migration, type I differentiation, and expansion of alloreactive effectors. In severely affected mucosa, we observed high levels of MxA, a protein specifically induced by type I IFN, and signal transducer and activator of transcription 1 (STAT1) phosphorylation, a critical step in the IFN-signaling pathway, along with increased numbers of plasmacytoid dendritic cells. These data challenge the current paradigm of cGVHD as a type II cytokine-driven disorder and support the model that oral cGVHD results from type I IFN-driven immigration, proliferation, and differentiation of T-bet(+) type I T effectors. The clinical trials are registered at http://www.clinicaltrials.gov as NCT00331968.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168793      PMCID: PMC2668847          DOI: 10.1182/blood-2008-07-168351

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

Review 1.  Innate immune functions of plasmacytoid dendritic cells.

Authors:  Wei Cao; Yong-Jun Liu
Journal:  Curr Opin Immunol       Date:  2006-11-20       Impact factor: 7.486

Review 2.  Type I interferon in systemic lupus erythematosus and other autoimmune diseases.

Authors:  Jacques Banchereau; Virginia Pascual
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

3.  Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity.

Authors:  Bradley W Blaser; Noah R Schwind; Seth Karol; Dennis Chang; Samuel Shin; Sameek Roychowdhury; Brian Becknell; Amy K Ferketich; Donna F Kusewitt; Bruce R Blazar; Michael A Caligiuri
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

4.  T-bet controls pathogenicity of CTLs in the heart by separable effects on migration and effector activity.

Authors:  Viviany R Taqueti; Nir Grabie; Richard Colvin; Hong Pang; Petr Jarolim; Andrew D Luster; Laurie H Glimcher; Andrew H Lichtman
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

5.  Type I interferon-associated cytotoxic inflammation in lichen planus.

Authors:  Joerg Wenzel; Marina Scheler; Julia Proelss; Thomas Bieber; Thomas Tüting
Journal:  J Cutan Pathol       Date:  2006-10       Impact factor: 1.587

Review 6.  Chronic graft versus host disease.

Authors:  Kristin Baird; Steven Z Pavletic
Journal:  Curr Opin Hematol       Date:  2006-11       Impact factor: 3.284

7.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

8.  Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

Authors:  Frank O Nestle; Curdin Conrad; Adrian Tun-Kyi; Bernhard Homey; Michael Gombert; Onur Boyman; Günter Burg; Yong-Jun Liu; Michel Gilliet
Journal:  J Exp Med       Date:  2005-07-04       Impact factor: 14.307

9.  T-bet is required for optimal proinflammatory CD4+ T-cell trafficking.

Authors:  Graham M Lord; Ravi M Rao; Hyeryun Choe; Brandon M Sullivan; Andrew H Lichtman; F William Luscinskas; Laurie H Glimcher
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

10.  Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs.

Authors:  Hiroyuki Yoneyama; Kenjiro Matsuno; Etsuko Toda; Tetsu Nishiwaki; Naoki Matsuo; Akiko Nakano; Shosaku Narumi; Bao Lu; Craig Gerard; Sho Ishikawa; Kouji Matsushima
Journal:  J Exp Med       Date:  2005-08-01       Impact factor: 14.307

View more
  47 in total

1.  Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses.

Authors:  Kathryn J Martires; Kristin Baird; Deborah E Citrin; Fran T Hakim; Steven Z Pavletic; Edward W Cowen
Journal:  Arch Dermatol       Date:  2011-09

2.  Emergence of T cells that recognize nonpolymorphic antigens during graft-versus- host disease.

Authors:  Hemalatha Rangarajan; Maryam Yassai; Hariharan Subramanian; Richard Komorowski; Megan Whitaker; Jack Gorski; William R Drobyski
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

3.  Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD.

Authors:  Johannes K-H Meier; Daniel Wolff; Steve Pavletic; Hildegard Greinix; Martin Gosau; Hartmut Bertz; Stefanie J Lee; Anita Lawitschka; Sharon Elad
Journal:  Clin Oral Investig       Date:  2010-09-22       Impact factor: 3.573

Review 4.  Oral Complications of Chronic Graft-Versus-Host Disease.

Authors:  Jane M Fall-Dickson; Steven Z Pavletic; Jacqueline W Mays; Mark M Schubert
Journal:  J Natl Cancer Inst Monogr       Date:  2019-08-01

5.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Authors:  Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-30       Impact factor: 5.742

6.  Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10.

Authors:  B Lamarthée; F Malard; C Gamonet; C Bossard; M Couturier; J-C Renauld; M Mohty; P Saas; B Gaugler
Journal:  Mucosal Immunol       Date:  2015-07-08       Impact factor: 7.313

Review 7.  Regulation of organogenesis and stem cell properties by T-box transcription factors.

Authors:  Yasuo Takashima; Atsushi Suzuki
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

8.  Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.

Authors:  Frances T Hakim; Sarfraz Memon; Ping Jin; Matin M Imanguli; Huan Wang; Najibah Rehman; Xiao-Yi Yan; Jeremy Rose; Jacqueline W Mays; Susan Dhamala; Veena Kapoor; William Telford; John Dickinson; Sean Davis; David Halverson; Haley B Naik; Kristin Baird; Daniel Fowler; David Stroncek; Edward W Cowen; Steven Z Pavletic; Ronald E Gress
Journal:  J Immunol       Date:  2016-09-30       Impact factor: 5.422

9.  Interleukin 17 is not required for autoimmune-mediated pathologic damage during chronic graft-versus-host disease.

Authors:  Xiao Chen; Rupali Das; Richard Komorowski; Jacques van Snick; Catherine Uyttenhove; William R Drobyski
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-17       Impact factor: 5.742

10.  Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.

Authors:  M M Imanguli; E W Cowen; J Rose; S Dhamala; W Swaim; S Lafond; B Yagi; R E Gress; S Z Pavletic; F T Hakim
Journal:  Leukemia       Date:  2014-02-28       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.